If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
SAN FRANCISCO, Sept. 22 (HSMN NewsFeed) — OrbusNeich today announced that the final 12-month clinical data from the global e-HEALING clinical study showed that the company’s Genous Bio-engineered R stent is safe and effective in real world use, includin…
Devices, Interventional Cardiology
OrbusNeich, e-HEALING, Genous Bio-engineered R stent
Posts from ‘September, 2009’
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Nice Safety and Efficacy with Real World Use of OrbusNeich’s Genous(TM) Bio-engineered R stent(TM)
OrbusNeich’s Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI
Results Presented at the 2009 Transcatheter Therapeutics Conference in San Francisco SAN FRANCISCO, Sept. 22 (HSMN NewsFeed) — OrbusNeich announced today that interim data from a prospective registry showed nice safety in a broad population of patien…
Devices, Interventional Cardiology
OrbusNeich, STEMI , Genous Bio-engineered R stent
Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2
ABBOTT PARK, Ill., Sept. Twenty one (HSMN NewsFeed) — Abbott (NYSE: ABT ) announced today it received approval from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM HIV O Plus test, the first fully automated blood screening test for HIV-1/HIV-2….
Diagnostics, HIV/AIDS, FDA
Abbott, PRISM HIV O Plus, HIV-1/HIV-2
Breakthrough Test Can Prevent Fatal Kidney Failure
GENTOFTE, Denmark, Sept. 21, 2009 –(HSMN NewsFeed) — Acute kidney injury has long been recognized as a devastating disorder which often arises as a complication of other serious illnesses. Despite great efforts to understand and treat this condition the …
Diagnostics
BioPorto, NGAL test
Medtronic, Inc. Launches Innovative Cement Delivery System for KYPHON(R) Balloon Kyphoplasty
KYPHON(R) Cement Delivery System Offers Out of Fluoroscopic Field Delivery and the Ability to Halt Bone Cement Flow On Demand MINNEAPOLIS–(HSMN NewsFeed)–Medtronic, Inc. (NYSE:MDT ), today announced the full U.S. launch of the KYPHON Cement Delivery S…
Devices, Orthopaedic, Neurosurgery
Medtronic, KYPHON, Balloon Kyphoplasty, Bone Cement, Cement Delivery
Moses Cone Regional Cancer Center Installs North Carolina’s First TomoTherapy(R) Treatment System
MADISON, WI - (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ:TOMO ) announced today that Moses Cone Health System has installed North Carolina’s first TomoTherapy cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C. The …
Devices, Oncology
TomoTherapy, Hi-Art, radiotherapy, VMAT, RapidArc
Guatemala Treatment Center Becomes First in Latin America to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
GUATEMALA CITY, Sept. 18 (HSMN NewsFeed) — Cancer patients in Guatemala and across Central America now have access to advanced radiotherapy treatments, including intensity-modulated radiotherapy (IMRT) with RapidArc® technology. Hope International C…
Devices, Oncology
Varian Laboratory Systems, IMRT, RapidArc
Cardinal Health Licenses Tillotson Patent for Nitrile Gloves
LEXINGTON, MA - (HSMN NewsFeed) - Tillotson Corp. today announced that Cardinal Health has licensed a Tillotson U.S. patent for disposable Nitrile Gloves. "We are very pleased to have Cardinal Health join almost three dozen U.S. and international l…
Devices, Licensing
Cardinal Health, Tillotson Corp, Nitrile Gloves
Calypso Pharmaceutical Closes $50 Million Venture Financing Round
Investment led by Skyline Ventures and Frazier Healthcare Ventures to Support New Indications and Commercial Expansion SEATTLE–(HSMN NewsFeed)–Calypso Clinical Technologies, Inc., a developer of real-time localization technology used for the precise tr…
Devices, Oncology, Venture Capital
Calypso Medical Technologies, GPS for the Body, radiotherapy
Michelson Diagnostics Awarded CE-Mark for Medical Use of Its VivoSight OCT Scanner in Europe and for Non-Clinical Applications Worldwide
Michelson’s Proprietary Multi-Beam OCT Scanner Provides Detailed Pics of Sub-Surface Skin Microstructure At Resolutions Currently Out of Reach of Ultrasound and MRI ORPINGTON, England, Sept. 17, 2009 –(HSMN NewsFeed) — Michelson Diagnostics has anno…
Devices, Diagnostics, Monitoring, Oncology, Regulatory
Michelson Diagnostics, VivoSight, Optical Coherence Tomography
